In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urovant Sciences Ltd.

Division of Roivant Sciences Inc.
www.urovant.com

Latest From Urovant Sciences Ltd.

Venture Funding Deals: Sumitomo Alliance With Roivant Takes Shape

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.

Deals Financing

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Business Strategies Commercial

Will 'Vant' Deal Really Fulfill Dainippon's Needs?

Sumitomo Dainippon's planned $3bn deal with Roivant goes some way to fulfilling the Japanese firm's strategic needs, but investors appear cool and questions remain.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • Keith Katkin, CEO
    Cornelia Haag-Molkenteller, MD, PhD, CMO
    Michael McFadden, Chief Commercial Officer
    David Hovland, PhD, SVP, Global Reg. Affairs
  • Contact Info
  • Urovant Sciences Ltd.
    Phone: 612254482
    5281 California Ave.
    Ste. 100
    Irvine, CA 92617
    USA
UsernamePublicRestriction

Register